Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G for Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS).
- Disclosed ownership: 5.6%.
- Date of event: 21 Jul 2025.
Deep Track Capital, LP - 21 Jul 2025 SCHEDULE 13G Report for Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- TARS
- Shares outstanding
- 42,017,143 shares
- Disclosed Ownership
- 2,352,960 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G
- Filing time
- 28 Jul 2025, 17:00:30 UTC
- Date of event
- 21 Jul 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 5.6% ownership in Tarsus Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (TARS) on 21 Jul 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 28 Jul 2025, 17:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 5.6% | 2,352,960 | 0 | 2,352,960 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 5.6% | 2,352,960 | 0 | 2,352,960 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 5.6% | 2,352,960 | 0 | 2,352,960 | /s/ David Kroin | David Kroin |